FDA examines cause of valsartan impurity

The US Food and Drug Administration (FDA) says a “major operation” is underway to investigate and address the “troubling finding” of a toxic impurity in some generic versions of valsartan that could cause cancer, leading the agency to also test all drugs in valsartan’s therapeutic class for traces of the toxic material.